Viatris Forms Eye Care Unit from Acquisitions
Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.
Viatris
Viatris Selling Biosimilars Unit to Biocon for $3 Billion
Viatris, the new US pharma created in the 2020 merger of Mylan and Pfizer’s Upjohn off-patent franchise, is selling its biosimilars portfolio to Biocon Biologics for up to $3.35 billion. Terms of the deal foresee Biocon paying $2 billion upfront, $1 billion in convertible preferred equity and $335 million in additional payments.
Upjohn/Mylan Merger Closes to Form Viatris
Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer stockholders owned about 57% of the outstanding shares of Viatris common stock and Mylan shareholders owned roughly 43%.
